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Transepithelial nasal potential difference (NPD) measurements assess ion conductance in the upper respiratory epithelium. NPD is useful
in assisting in the diagnosis of classical and atypical cystic fibrosis (CF) and of cystic fibrosis transmembrane regulator (CFTR)-related
disorders, as well as for monitoring the effect of pharmacological agents and gene transfer approaches to correct the abnormalities of ion
transport in CF. The article summarizes the objectives and the principle of NPD measurements, describes a hands-on protocol of the
procedure and provides quality control measures, practical hints and troubleshooting.
D 2004 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Basic defect; Cystic fibrosis; Diagnosis; Nasal potential difference1. Objectives
Cystic fibrosis (CF) is characterized by abnormal air-
way epithelial sodium (Na+) and chloride (Cl) transport
that reflects defects in the cystic fibrosis transmembrane
regulator (CFTR) gene. Measurements of transepithelial
potential difference (PD) have been performed in the nose
(and lower airways) of human subjects [1], and patients
with CF have a characteristic pattern of bioelectric prop-1569-1993/$ - see front matter D 2004 European Cystic Fibrosis Society. Publish
doi:10.1016/j.jcf.2004.05.032
Abbreviations: AT; anterior turbinate; IT, inferior turbinate; NPD, nasal
potential difference; PD, potential difference; PE, polyethylene.
* Corresponding author. Tel.: +49-511-532-2920; fax: +49-511-532
6723.
E-mail address: tuemmler.burkhard@mh-hannover.de (B. Tu¨mmler).erties which reflect accelerated Na+ transport (absorption),
and (absent) or reduced CFTR-mediated Cl secretion [1–
4]. These bioelectric indices have been validated by
extensive in vitro studies of freshly excised human tissues,
as well as in vitro studies of airway epithelial cells in
culture, including intracellular ion-selective microelectrode
impalements, as well as characterization of the multiple
components of the transepithelial barrier, i.e., the apical
and basolateral cell membranes and the paracellular (shunt)
pathway. Because in vivo measurement of nasal potential
difference (NPD) can define ion transport abnormalities
that are characteristic of CF, this technique may be useful
in assisting in the diagnosis of cystic fibrosis, as well as
for monitoring the effect of pharmacological agents and
gene transfer approaches to correct the abnormalities of ion
transport [3–6].ed by Elsevier B.V. All rights reserved.
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Active ion transport by the respiratory epithelium is
thought to play an important role in the regulation of the
volume and composition of airway surface liquid, and ulti-
mately contributes to the efficiency of mucociliary and cough
clearance. In vitro, freshly excised airway epithelial tissues
can be studied in Ussing chambers, and when the trans-
epithelial electric PD is clamped to zero (‘‘short-circuited’’),
basal patterns of ion transport can be directly determined by
isotopic measurements of the transepithelial flux of specific
electrolytes, including Na+ and Cl ions. Thus, there are
defined correlates of ion flux and bioelectric parameters of
active ion transport and tissue (barrier) resistance. Because
the PD generated by the airway epithelium reflects the
relationship between the magnitude and direction of the net
transepithelial active ion transport and the epithelial ion
conductance, the transepithelial PD (voltage) serves as an
index of ion transport and ionic conductances (permeability).
The net flux of ions cannot be measured in vivo, but the
interpretation of bioelectric changes can be inferred from
principles developed from studies of human tissues in vitro,
and from basic principles of ion transport and membrane
physiology. The general principle for recording transepithe-
lial PD is that the subcutaneous space is isoelectric at all
locations in the human body; thus, the transepithelial
voltage can be quantified in magnitude and polarity, by
referencing the PD to ‘zero’ in submucosal space. In brief, a
subcutaneous reference electrode located anywhere in the
body would be the equivalent to a reference electrode
located in the submucosal space of the nasal epithelium [4].
The voltage between the reference electrode and the
exploring electrode accurately reflects the transepithelial
PD, assuming the system is appropriately established. The
simplest way for this to be demonstrated is that abrasion of
the epithelium reduces the transepithelial potential to zero,
which demonstrates that the development of transepithelial
PD requires an intact epithelial surface, and the subcutaneous
reference electrode (in the forearm) is isoelectric with sub-
mucosal space in the nasal cavity. The polarity and magni-
tude of the voltage is also in the range of values recorded in
vitro in multiple human cell systems. Finally, the local
application of drugs also provides clues to the nature of the
active ion transport process across the epithelium [4,5].
Specifically, drugs with relatively specific actions, such as
the Na+ conductance inhibitor amiloride, inhibits Na+ entry
across luminal membrane of the nasal epithelial cells in a
dose-dependent fashion, which results in the reduction of
transepithelial difference in vivo. Similarly, the measurement
of Cl conductance (‘‘secretion’’) can be assessed by estab-
lishing a gradient for Cl ion to exit the luminal (apical)
membrane of the airway cell by perfusing the surface of the
epithelium with a Cl-free solution, whereby Cl ions are
replaced by an impermeant anion, such as gluconate. Phar-
macological activation of the Cl channel may be tested by
prior establishment of an electrogenic gradient for Cl to exitthe cell (and thereby increase, i.e., hyperpolarize, the trans-
epithelial PD). Although the role of the paracellular shunt
cannot be well defined in a quantitative sense in vivo, the
magnitude of the apical membrane ion selectivity far exceeds
any selectivity of the shunt, and therefore the latter plays a
minor role in the overall value of the transepithelial PD.3. Basic protocol [4,7,8]
NPD is measured between a fluid-filled exploring bridge
positioned on the airway surface and a fluid-filled reference
bridge in the subcutaneous space. This approach also
ensured application of drugs directly at the locus of PD
measurement (‘Superfusion’ method). The regimen uses
balanced Ag/AgCl electrodes (or saturated calomel half-
cells) connected to a high-impedance voltmeter, an explor-
ing bridge (double lumen catheter) and a subcutaneous
reference electrode (22- to 24-gauge (ga.) needle) that are
both perfused with isotonic Ringer’s solution. The tip of the
exploring tubing is placed onto respiratory mucosa under
the concha nasalis inferior. To study the response of PD to
several drugs, the superfusion solutions are applied via the
exploring electrode connected by a three-way valve or
through the second lumen of a double-barreled catheter.
3.1. Preconditions
Compliance: NPD with superfusion is possible in infants
and in children older than 5 years with intact nasal mucosa
(without, e.g., acute rhinitis).4. Materials: superfusion solutions
Solution A: Custom Ringer’s. 135 mM NaCl; 1.2 mM
MgCl2; 2.25 mMCaCl2; 2.4 mMK2HPO4; 0.4 mMKH2PO4.
Solution B: 0.1 mM amiloride hydrochloride (HCl) in Ring-
er’s solution. Solution C: Zero Cl solution ( + amiloride):
135 mM sodium gluconate, 1.2 mM MgSO4, 2.2 mM
Calcium gluconate, 2.4 mM K2HPO4, 0.4 mM KH2PO4,
0.1 mM amiloride HCl. Solution D: 0.01 mM isoprotenerol
HCl in solution C (caution: vials of isoprotenerol contain
Cl). Solution E: 0.1mMATP in solution D. Check that pH is
7.4, range 7.0–7.6. Solutions A, B, and Cmay be refrigerated
for up to 3 months or frozen for up to 6 months, solutions D
and E are freshly prepared within 2 h prior to use. Prior to use,
all solutions must be filtered with a 0.22-Am filter.5. Equipment
5.1. Exploring electrode
The exploring electrode is an isotonic NaCl/Ringer’s
saline-perfused exploring bridge positioned on the airway
D. Schu¨ler et al. / Journal of Cystic Fibrosis 3 (2004) 151–155 153surface. Exploring bridges are prepared either by filling
lengths of polyethylene (PE) tubing (PE-50 to PE-160) with
3 M KCl in 4% agar or by a fluid-filled double-lumen
catheter continuously perfused with warmed (24–37 jC)
gassed isotonic NaCl/Ringer’s saline (0.2–0.4 ml/min).
Contact with the nasal surface is ensured by perfusion.
The exploring bridge can consist of a vinyl catheter (exam-
ple: umbilical vessel catheter, 5Ch 1.7mm). Most catheters
can be used repeatedly following gas sterilisation.
5.2. Reference electrode
The reference electrode is an isotonic NaCl or Ringer’s
saline-perfused bridge in the subcutaneous space of the
lower arm. The reference bridge is a 19- to 24-ga. needle
that contains isotonic Ringer.
5.3. Measuring electrode, voltmeter
A high-input impedance (108–1012 V), low-resistance
voltmeter amplifier is connected to two silver/silver chloride
half cells inserted in gas tight Erlenmeyer flasks which are
filled with 3 M KCl solution. These Erlenmeyer flasks are
connected via 3 M KCl 4% agar gel bridges in gas tight glass
tubes with two other Erlenmeyer flasks filled with isotonic
NaCl solution. From those flasks, both the subcutaneous
reference electrode and the exploring catheter are connected
via isotonic NaCl 4% agar gel bridges in normal infusion
tubings. This described regimen of agar gel bridges avoids
offset potentials and exhibits stable and reproducible poten-
tial for several years. Alternatively, Ag/AgCl electrodes
connected by a Luer lock port with the flow-through system
are possible. Other groups use calomel half-cells connected
via a Ringer–4% agar bridge to a high-impedance voltmeter.
5.4. Data recording
Data are recorded on a chart recorder or a computerized
recording system. Indicate the trace zero, voltage span, and
chart speeds. The offset voltage should initially set to zero.
If the final offset voltage at the termination of the procedure
differs from the initial offset by more than 5 mV, designate
the trace ‘invalid’.6. Measuring the NPD1
6.1. Protocol
(1) Prepare reagents.
(2) Prior to each procedure, check the set-up and use new
tubing circuits to avoid inter-patient contamination. A fresh
sterile exploring catheter is used for each measurement.1 Modified NPD protocols are available from T. Leal [11] and M. Hug
(email: hugma@web.de).(3) The perfused solutions should be warmed so that the
temperature exiting from the exploring catheter is in the
range from 32 to 37 jC (Some laboratories work at ambient
room temperature, although it should be noted that a warmed
nasal perfusate gives a greater Cl conductance [9]).
(4) Check the zero offset. Prior to use, the electrodes are
calibrated by placing the reference electrode in close contact
with the exploring electrode to test asymmetry before and
after examination of each subject. When electrode pairs
differ in PD by more than 1 mV, the bridges are discarded.
(5) Check the conductivity. The conductivity of the
bridges is assessed by a preliminary measurement of skin
PD at the palm of the hand. If a stable PD cannot be
recorded ( < 3% of cases), the reference bridge is replaced,
the perfusion bridge flushed, and the test repeated. Values
for baseline PD measurements are accepted if PD measure-
ments are stable for more than 3 s and if the PD measure-
ment at the palm of the hand are comparable at the
beginning and end of the study.
(6) Position of the subject. The subject should sit relaxed
and comfortably in an armchair so that the nasal perfusate
flushes from the nostril without any discomfort.
(7) Insert the exploration catheter into the nostril using an
endoscope or otoscope to visualize the inferior turbinate (IT).
Record voltage at the tip of anterior turbinate (AT), advance
the catheter through the inferior meatus and record voltage
every 0.5–1 cm, using the tip of the AT as landmark. The AT
of the IT is a convenient anatomic reference point (squamous
epithelium). Values of a measurement are accepted if the PD
of the AT at the beginning and the end of the procedure is
comparable (F 5 mV).
(8) Place the catheter at the site of most negative signal.
Fix the exploring catheter with tape on the patient’s fore-
head. The catheter should have enough tension to stay at the
IT. Confirm position and depth of tip with endoscope or
otoscope.
(9) Start continuous voltage recording.
(10) Start perfusion with solution A. For each solution,
NPD is measured for a minimum of 3 min. A steady voltage
tracing should be achieved for at least 15 s ( < 3 mV/min
drift). All solutions are perfused at 5 ml/min (there is no
consensus about the optimal flow rate that vary by labora-
tory between 1.5 and 5 ml/min, although low flow rates
have been demonstrated to cause substantial variability
[10]). Solution changes should be marked in the trace.
(11) Replace solution A by solution B.
(12) Replace solution B by solution C.
(13) Replace solution C by solution D.
(14) Replace solution D by solution E.
(15) Stop perfusion, verify the position of the tip of the
catheter, then record AT potential again.
(16) Remove the catheter, replace solution E by solution
A and flush with solution A to remove prior reagents.
(17) Repeat steps (7)–(15) in the other nostril.
(18) By the end of the measurement, repeat steps (4) and
(5).
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There is still substantial variation between laboratories
with respect to the absolute PD values, but the differential
responses of CF subjects and non-CF controls are clearly
discerned. The basal PD in non-CF subjects is typically
 20F 10 mV. The change in PD with amiloride super-
perfusion is 11F 6 mV. The cumulative responses to Cl-
free solution and to isoproterenol sum up to about
 19F 11 mV. The mean basal PD of CF patients is
approximately double the value in controls,  45F 10
mV. Amiloride has a larger inhibitory effect in CF patients,
30F 15 mV. There is no or only a minimal response to
Cl-free solution and isoproterenol in CF patients which
can be taken as the most sensitive and specific criterion to
make a CF diagnosis. The PD response to ATP in normals
( 5F 3 mV) is typically increased in CF patients to
about  10F 5 mV.
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France).7. Troubleshooting and practical hints
Variability of NPD measurements can reduce the power
of studies using NPD as outcome measures. They may
cover the following: the material used (catheters, electro-
des); the offset of the electrodes; the positioning and
fixation of the catheter; the measure itself (stability of the
measure, duration of the experiment); the tested subjects
(age, clinical status). The following practical hints may be
helpful for in-house validation and standardization of the
procedure.
7.1. The material
The exploring bridge must be a double lumen catheter
with the opening of both lumina at the same site. One lumen
is filled with a fluid allowing ionic conductance and
connected to a high-impedance voltmeter via the electrode.
The second lumen is perfused with the different solutions
using a pump that provides a continuous flow throughout
the perfusion period.
The types of catheter used vary according to the operators.
The most frequently used are: 8-Fr Foley paediatric urinary
catheter, 4 Fr double-lumen central venous catheter, hand-
held single-lumen PE-50 tubing, umbilical vessel catheter.
Some operators modify the Foley catheter by cutting the
balloon area and then sticking it to the distal part. At the
Necker Enfants Malades hospital, the Ethics Committee
pointed out that this procedure alters and desterilizes a
material designed for single use. Besides, the distal part
can be inhaled. Hence, the cutting of catheters is discouraged.
The walls of the catheter must be rigid enough to wedge
securely into the right position. Silicone appears to be a
good compromise between the tolerance of the experimen-
tation by the patient and the commodity of use for the
operator. The diameter of the catheters is also a source ofvariability because the catheters with a small diameter tend
to slip out of position, which could result in inaccurate
measurements. For adults, and children older than 8 years of
age, a catheter with external diameter of 2.7 mm may be
used. The catheter could be marked at 0.5-cm intervals in
order to control the position of fixation. The Hannover
group uses an umbilical vessel catheter (5Ch 1.7 mm) that
allows correct positioning of the tip in the nostril and
fixation by tape on the forehead with minimal discomfort
for the subject. A catheter has been developed for the
investigation of infants.2
The fluid filling the bridge linked to the exploring
electrode is either the Ringer’s solution in 4% agar [1], or
an equal mixture of Ringer’s lactate and electrocardiograph-
ic cream [3]. In the second case, the two components must
be gently mixed and left to set at least 1 h before experi-
mentation, in order to have the least amount of bubbles in
the solution.
The reference electrode is generally placed on the inner
forearm after abrading the skin. This operation is necessary
to create a suitable site of zero potential. A handheld motor
unit containing a diamond-tipped dental burr can be used.
The reference electrode is taped over this site and diluted
(1:1) electrode gel is injected through the hole into the
electrode to allow electrical contact [3]. Other operators
prefer a reference bridge with a 19- or 21-ga. needle filled
with Ringer’s 4% agar inserted into the subcutaneous space
of the forearm linked to the reference electrode [1,4]. This is
an additional apparatus that can frighten children, but has
the advantage of having a direct access to the subcutaneous
space of the forearm, which is isoelectric with the submu-
cosal space of the airway epithelia.
7.2. Offset of the electrodes
Prior to recordings, the offset of the electrodes must be
measured and appropriate corrections made to record val-
ues. Under short-circuit conditions, 0 mV is obtained when
the reference electrode is in contact with the exploring
electrode. Values > F 5 mV are unacceptable and the
electrodes must be changed.
The conductivity of the bridge must be assessed by
preliminary measurements of skin PD. The PD of the tip
is noted. Acceptable values range from  30 mV and
upwards. If a stable PD is not recorded, the bridges must
be changed or the skin more deeply abrased or the subcu-
taneous skin bridge changed.
7.3. Positioning and fixation of the catheter
Proper positioning along the IT is critical to obtain
accurate measures. It is a very important moment in the
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right site or not properly fixed, this leads to inaccurate and
possibly unstable measurements. The catheter must be
introduced into the nostril under visual guidance with an
otoscope and a nasal speculum or a plastic autoscope
speculum. The anterior tip of the IT provides a convenient
anatomic reference point. Initial PD measurements are
made at that site. The bridge is then advanced gently
through the inferior meatus along the floor of the nose and
a PD profile of the turbinate is obtained by recording 5 s
measurements at 0.5, 1, 1.5, 2 and 3 cm posterior to the
anterior tip. The PD in the anterior tip is low; there is a
sharp increase under the turbinate and a subsequent grad-
ual decrease more posteriorly. The catheter is withdrawn
slowly from the 3-cm site while readings are noted. A
maximal stable (F 1 mV) PD is sought and recorded if the
voltage is stable for more than 10 s. The maximal stable
PD is usually obtained 3 cm from the anterior tips of the
turbinate. It is verified by slow rotation of the catheter that
the value is maximal.
The fixation must avoid the slipping out of the catheter
because of the leaning forward position of the patients and the
continuous perfusion of the fluid which can moister the
fixation. Some operators ask the patient to hold the catheter
and to maintain this position during the whole procedure.
However, this carries the risk of moving the catheter from the
initial site of measurement and is difficult to obtain in
children. Fixation of the catheter with tape at the forehead
is recommended.
7.4. NPD measurements
The exploring bridge is perfused with drug-free Ring-
er’s at a perfusion rate as low as 0.2 ml/min for at least
30 s. When a stable PD is recorded, the drug-free
Ringer’s perfusion is stopped and perfusion of drug is
initiated. The perfusion rate throughout the experimenta-
tion must be at least 4 ml/min. It has been demonstrated
that a slower flow (2.2 versus 5 ml/min) is a source of
variability [10]. The effects of the drug must be recorded
during at least 180 s for the following reasons. First, the
new perfusate reaches the catheter approximately 45 s
following solution change because of the 3 ml dead
space of the perfusion system. Second, a stable voltage
plateau must be achieved. The equilibration time after
adding amiloride or isoproterenol is typically about 1
min. In contrast, after the change to the low Cl solution
NPD is stable only after 4 min. It is therefore mandatory
to consider that the last 60 s are taken as the final
reading for each solution. Recordings for 3 min after
adding amiloride or isoproterenol and for 5 min after
changing to low Cl solution are recommended. In any
case, if a steady state is not obtained after this delay, the
recording must be prolonged. Zero offset and conduc-
tance should be checked at the beginning and the end of
the procedure.The solutions can be administered at room temperature.
However, administration of drug at 37 jC improves the
sensitivity of the measurement.
7.5. The patients
Acute inflammation of the nasal respiratory epithelium
that disrupts the epithelial integrity, localized hemorrhage or
viral infection can artificially impair detection of NPD.
Therefore, it is recommended to delay the measure for 1
month if there is a history of hay fever, chronic rhinitis or
any symptoms of acute rhinitis in the second week prior the
study and not to include regular smokers. Age must be
considered because PD values are significantly lower in
older men [1].
Finally, differences in operator skill and technique are the
most important causes of the differences in measurement
variability. This can be minimized by careful operator
training, standardization of measurement protocols and
ongoing monitoring of individual operator performance.References
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